Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Central PharmaceuticalsDHA:CENTRALPHL 65 PS Ratio is 35.10 as of Aug. 21, 2026, which is 139% above its 10-year median of 14.67. GuruFocus rates DHA:CENTRALPHL with a GF Score™ of 65/100 and a GF Value™ of BDT12.11 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 949 Drug Manufacturers companies, Central Pharmaceuticals ranks worse than 96.1% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Central Pharmaceuticals's share price is BDT10.60.
Central Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0.30. Hence, Central Pharmaceuticals's PS Ratio for today is 35.10.
Warning Sign:
Central Pharmaceuticals Ltd stock PS Ratio (=37.09) is close to 1-year high of 38.08.
The historical rank and industry rank for Central Pharmaceuticals's PS Ratio or its related term are showing as below:
DHA:CENTRALPHL'
s PS Ratio Range Over the Past 10 Years
Min: 3.49 Med: 14.67 Max: 288.89
Current: 35.1
During the past 13 years, Central Pharmaceuticals's highest PS Ratio was 288.89. The lowest was 3.49. And the median was 14.67.
DHA:CENTRALPHL's PS Ratio is ranked worse than 96.1% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs DHA:CENTRALPHL: 35.10
Central Pharmaceuticals Ltd revenue per share has been in decline for the last 5 years.
During the past 3 years, the average Revenue per Share Growth Rate was 8.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -28.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -30.70% per year.
During the past 13 years, Central Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 8.30% per year. The lowest was -56.10% per year. And the median was -23.30% per year.
Central Pharmaceuticals (DHA:CENTRALPHL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:CENTRALPHL vs ZTS, UTHR, VTRS: PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Central Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Central Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Central Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Central Pharmaceuticals's Share Price of today is BDT10.60. Central Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT0.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Central Pharmaceuticals (DHA:CENTRALPHL) has a PS Ratio of 35.10 as of Aug. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Central Pharmaceuticals and its competitors. This is 139% above median its historical median of 14.67. Over the past decade, Central Pharmaceuticals' PS Ratio has ranged from 3.49 to 288.89. According to the industry distribution chart, Central Pharmaceuticals ranks #912 out of 949 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Central Pharmaceuticals' PS Ratio too high?
Central Pharmaceuticals' current PS Ratio of 35.10 is 139% above median its 10-year median of 14.67. Over the past 10 years, this metric has ranged from a low of 3.49 to a high of 288.89. The Drug Manufacturers industry median PS Ratio is 2.36. Central Pharmaceuticals' value of 35.10 is 1387.3% above this industry median. Based on the distribution chart, Central Pharmaceuticals ranks #912 out of 949 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Central Pharmaceuticals has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Central Pharmaceuticals ranks #912 out of 949 companies for PS Ratio. This places Central Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 2.36. Central Pharmaceuticals' value of 35.10 is 1387.3% above this benchmark. Historically, Central Pharmaceuticals' own PS Ratio has ranged from 3.49 to 288.89 over the past decade. While the company's 10-year median is 14.67 vs. the industry median of 2.36, Central Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.36, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Central Pharmaceuticals's current PS Ratio of 35.10 is 1387.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Central Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Central Pharmaceuticals's current PS Ratio is 35.10, which is 139% above median its own 10-year median of 14.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT12.11, compared to a current price of BDT10.60 — trading 12.5% below its estimated fair value. The current PS Ratio is 35.10, which is 139% above median its 10-year median of 14.67 and 1387.3% above the Drug Manufacturers industry median of 2.36. Central Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current PS Ratio is 35.10 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?
Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT10.60 is trading 12.5% below its estimated GF Value™ of BDT12.11.
GuruFocus considers Central Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for DHA:CENTRALPHL:
PS Ratio: 35.10 (139% above median its 10-year median of 14.67)
GF Value™: BDT12.11 vs. price of BDT10.60 (12.5% below fair value)
Industry Position: 1387.3% above the Drug Manufacturers median (#912 of 949)
No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
65GF Score
Get the complete analysis for DHA:CENTRALPHL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:CENTRALPHL has been successfully added to your 
